Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | ESMO 2021 highlights in colorectal cancer

Claudia Cardone • 19 Sep 2021
ESMO 2021
Colorectal Cancer Adagrasib Atezolizumab Bevacizumab Cetuximab FOLFOXIRI Ipilimumab Nivolumab Temozolomide
AtezoTRIBE KRYSTAL-1 MAYA

Claudia Cardone, MD, Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”, Naples, Italy, discusses her highlights from the European Society for Medical Oncology (ESMO) 2021 Congress, including the AtezoTRIBE trial (NCT03721653), the MAYA trial (NCT03832621), and the KRYSTAL-1 trial (NCT03785249). This interview took place at the ESMO 2021 Congress.

More from Claudia Cardone

1:40
ESMO: Young Oncologists Track
Claudia Cardone • 19 Sep 2021
0:59
Improvements for women in oncology
Claudia Cardone • 19 Sep 2021
0:48
Benefits of social media in oncology
Claudia Cardone • 19 Sep 2021

Related Videos

0:47
The key to precision medicine in colorectal cancer
Scott Kopetz • 8 Apr 2024
0:40
Clinical targeting of adaptive resistance in colorectal cancer
Scott Kopetz • 8 Apr 2024
1:47
Adaptive resistance in BRAF- and KRAS-mutated colorectal cancer
Scott Kopetz • 8 Apr 2024
1:19
How can we implement MRD testing in colorectal cancer?
Paolo Manca • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals